Antares Pharma Appoints Tram Bui as Vice President of Corporate Communications and Investor Relations
August 10 2020 - 7:00AM
Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a
pharmaceutical technology company, today announced the appointment
of Tram Bui as Vice President of Corporate Communications and
Investor Relations. Ms. Bui will succeed Jack Howarth, Vice
President of Corporate Affairs, upon his retirement on August 31,
2020. Tram will report to Fred Powell, Antares Pharma’s Chief
Financial Officer.
“I am excited to welcome Tram to Antares to lead
our corporate communications and investor relations strategy. We
look forward to leveraging her extensive industry experience and
strong relationships with the investment community as the Company
continues on its growth trajectory,” said Fred M. Powell, Executive
Vice President and Chief Financial Officer of the Company. “I would
also like to thank Jack for his dedication and many contributions
to the company since 2012. He has been instrumental to the
development of the Company’s communications strategy and we wish
him the best of luck in his retirement.”
Ms. Bui joins Antares Pharma with over 15 years
of equity research, communications and investor relations
experience. Most recently, she served as Senior Vice President,
Investor Relations at The Ruth Group, a boutique investor relations
and communications firm specializing in life science and medical
technology industries. Prior to The Ruth Group, Ms. Bui
served as a Director at KCSA Strategic Communications, a public and
investor relations agency, focused on developing successful
investor communications platforms and capital raises for a broad
base of public healthcare companies. Previously, she was a
buy-side healthcare analyst for a small cap fund at Lazard Asset
Management and served as an institutional equity sales associate at
CJS Securities. Ms. Bui received her Bachelor of Science in
Marketing from the University of New Orleans.
About Antares Pharma
Antares Pharma, Inc. is a pharmaceutical
technology company focused primarily on the development and
commercialization of self-administered injectable pharmaceutical
products using advanced drug delivery auto injector
technology. The Company has a portfolio of proprietary and
partnered commercial products with several product candidates in
various stages of development, as well as significant strategic
alliances with industry leading pharmaceutical companies including
Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals,
Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd.
(Idorsia). Antares Pharma’s FDA approved products include
XYOSTED® (testosterone enanthate) injection, OTREXUP®
(methotrexate) injection for subcutaneous use and Sumatriptan
Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: Teva’s successful
commercialization of teriparatide injection in Europe and future
revenue from the same; the uncertainty regarding the duration,
scope and severity of the COVID-19 pandemic and the mitigation
measures and other restrictions implemented in response to the same
and the impact on reinstated 2020 full-year revenue guidance,
demand for our products, new patients and prescriptions, future
revenue, product supply, and our overall business, operating
results and financial condition; market acceptance, adequate
reimbursement coverage and commercial success of XYOSTED® and
future revenue from the same; successful development including the
timing and results of the clinical bridging and Phase 3 clinical
trial of the drug device combination product for Selatogrel with
Idorsia Pharmaceuticals and FDA and global regulatory approvals and
future revenue from the same; market acceptance of Teva’s generic
epinephrine auto-injector product and future revenue from the same;
the ability of Lunatus to obtain regulatory approvals for XYOSTED
in Saudi Arabia and UAE and successfully commercialize the product
and future revenue from the same; our expectations regarding
whether the FDA will pursue withdrawal of approval for AMAG
Pharmaceuticals Inc.’s Makena® subcutaneous auto injector following
the recent FDA advisory committee meeting and future prescriptions,
market acceptance and revenue from Makena® subcutaneous auto
injector; Teva’s ability to successfully commercialize VIBEX®
Sumatriptan Injection USP and the amount of revenue from the same;
continued growth of prescriptions and sales of OTREXUP®; the
timing and results of the Company’s or its partners’ research
projects or clinical trials of product candidates in development;
actions by the FDA or other regulatory agencies with respect to the
Company’s products or product candidates of its partners; continued
growth in product, development, licensing and royalty revenue; the
Company’s ability to meet loan extension and interest only payment
milestones and the ability to repay the debt obligation to Hercules
Capital; the Company’s ability to obtain financial and other
resources for its research, development, clinical, and commercial
activities and other statements regarding matters that are not
historical facts, and involve predictions. These statements involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contact:
Tram BuiVice President, Corporate Communications
and Investor Relations609-359-3020tbui@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Sep 2023 to Sep 2024